Evidence map›Paper›PMID 34535480›Full record

ArticleBMJ open2021

Delirium and neuropsychological outcomes in critically Ill patients with COVID-19: a cohort study.

Jacqueline Ragheb, Amy McKinney, Mackenzie Zierau, Joseph Brooks, Maria Hill-Caruthers, Mina Iskander, Yusuf Ahmed, Remy Lobo, Graciela Mentz, Phillip E Vlisides

Abstract read
In one paragraph

Article in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Infectious Diseases.Advances in neurobiology · 2024
    Review
  8. Observational
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Ischemic and Hemorrhagic Cerebrovascular Events Related to COVID-19 Coagulopathy and Hypoxemia.International journal of environmental research and public health · 2022
    Review
  15. Therapeutic Approaches to the Neurologic Manifestations of COVID-19.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022
    Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jacqueline Ragheb *Anesthesiology, Michigan Medicine, Ann Arbor, Michigan, USA.
Amy McKinney *Anesthesiology, Michigan Medicine, Ann Arbor, Michigan, USA.
Mackenzie ZierauAnesthesiology, Michigan Medicine, Ann Arbor, Michigan, USA.
Joseph BrooksAnesthesiology, Michigan Medicine, Ann Arbor, Michigan, USA.
Maria Hill-CaruthersAnesthesiology, Michigan Medicine, Ann Arbor, Michigan, USA.
Mina IskanderNew York Medical College, Valhalla, New York, USA.
Yusuf AhmedAnesthesiology, Michigan Medicine, Ann Arbor, Michigan, USA.
Remy LoboRadiology, Michigan Medicine, Ann Arbor, Michigan, USA.
Graciela MentzAnesthesiology, Michigan Medicine, Ann Arbor, Michigan, USA.
Phillip E VlisidesAnesthesiology, Michigan Medicine, Ann Arbor, Michigan, USA pvliside@med.umich.edu.ORCID 0000-0003-3899-5536

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo characterise the clinical course of delirium for patients with COVID-19 in the intensive care unit, including postdischarge neuropsychological outcomes.

designRetrospective chart review and prospective survey study.

settingIntensive care units, large academic tertiary-care centre (USA).

participantsPatients (n=148) with COVID-19 admitted to an intensive care unit at Michigan Medicine between 1 March 2020 and 31 May 2020 were eligible for inclusion. PRIMARY AND SECONDARY OUTCOME MEASURES: Delirium was the primary outcome, assessed via validated chart review method. Secondary outcomes included measures related to delirium, such as delirium duration, antipsychotic use, length of hospital and intensive care unit stay, inflammatory markers and final disposition. Neuroimaging data were also collected. Finally, a telephone survey was conducted between 1 and 2 months after discharge to determine neuropsychological function via the following tests: Family Confusion Assessment Method, Short Blessed Test, Patient-Reported Outcomes Measurement Information System Cognitive Abilities 4a and Patient-Health Questionnaire-9.

resultsDelirium was identified in 108/148 (73%) patients, with median (IQR) duration lasting 10 (4-17) days. In the delirium cohort, 50% (54/108) of patients were African American and delirious patients were more likely to be female (76/108, 70%) (absolute standardised differences >0.30). Sedation regimens, inflammation, delirium prevention protocol deviations and hypoxic-ischaemic injury were likely contributing factors, and the most common disposition for delirious patients was a skilled care facility (41/108, 38%). Among patients who were delirious during hospitalisation, 4/17 (24%) later screened positive for delirium at home based on caretaker assessment, 5/22 (23%) demonstrated signs of questionable cognitive impairment or cognitive impairment consistent with dementia and 3/25 (12%) screened positive for depression within 2 months after discharge.

conclusionPatients with COVID-19 commonly experience a prolonged course of delirium in the intensive care unit, likely with multiple contributing factors. Furthermore, neuropsychological impairment may persist after discharge.

Indexed as

COVID-19DeliriumAftercareCohort StudiesCritical IllnessFemaleHumansIntensive Care UnitsMalePatient DischargeProspective StudiesRetrospective StudiesSARS-CoV-2adult intensive & critical careCOVID-19delirium & cognitive disordersneurological injury

Identifiers

PMID34535480
PMCPMC8450964

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.